Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 10, 2023.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
AI could revolutionize patient advocacy by bridging communication gaps between patients and providers, and the synergy of medicine and AI offers a promising avenue for enhanced patient care and operational efficiency.
In this episode, Barry J. Byrne, MD, PhD, director of the Powell Gene Therapy Center at the University of Florida, discussed the recent FDA approval of Santhera Pharmaceuticals investigational agent vamorolone and important efficacy and safety information from the phase 2b VISION-DMD study.
In this edition of NeuroVoices, the chief medical officer of NeuroTherapia provided insight on promising phase 1b data assessing NTRX-07, a CBR2-targeting agent in development for patients with early-stage Alzheimer disease.
Amit Bar-Or, MD, FRCPC, provides an overview of the history of BTKi’s as well as what makes this class of drug a promising target for relapsing and remitting forms of MS.
The professor and chair of neurology at Virginia Commonwealth University discussed a study conducted among neurologists that revealed healthcare disparities in the treatment of myasthenia gravis, particularly related to access to care and therapeutics. [WATCH TIME: 5 minutes]